Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA1D | P25100 | 1/20 | 0.57 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.57 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.57 |
| ▸ | HTR1A | P08908 | 4/20 | 0.55 |
| ▸ | DRD4 | P21917 | 1/20 | 0.53 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 5/20 | 0.51 |
| ▸ | HTR2A | P28223 | 3/20 | 0.51 |
| ▸ | HTR7 | P34969 | 2/20 | 0.51 |
| ▸ | HTR6 | P50406 | 2/20 | 0.51 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | FAAH | O00519 | 3/20 | 0.47 |
| ▸ | DRD3 | P35462 | 3/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.47 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.46 |
| ▸ | TTR | P02766 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28811543 | 0.87 | ADRA1D (0.46) | ADRA1DADRA1AADRA1BHTR1ADRD4 | |
| SCHEMBL11153275 | 0.84 | HTR1A (0.55) | ADRA1DADRA1AADRA1BHTR1ADRD4 | |
| SCHEMBL2090844 | 0.82 | HTR1A (0.55) | ADRA1DADRA1AADRA1BHTR1ADRD4 | |
| SCHEMBL8828520 | 0.82 | CYP2D6 (0.56) | ADRA1DADRA1AADRA1BHTR1ADRD4 | |
| SCHEMBL31096308 | 0.81 | DRD4 (0.55) | ADRA1DADRA1AADRA1BHTR1ADRD4 | |
| SCHEMBL2095305 | 0.81 | DRD4 (0.52) | ADRA1DADRA1AADRA1BHTR1ADRD4 | |
| SCHEMBL3209314 | 0.81 | DRD2 (0.57) | ADRA1DADRA1AADRA1BHTR1ADRD4 | |
| SCHEMBL2091264 | 0.81 | DRD2 (0.57) | ADRA1DADRA1AADRA1BHTR1ADRD4 | |
| SCHEMBL2094159 | 0.80 | DRD2 (0.58) | ADRA1DADRA1AADRA1BHTR1ADRD4 | |
| SCHEMBL6751057 | 0.79 | KDM4E (0.61) | ADRA1DADRA1AADRA1BHTR1ADRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150057290-A1 | METHOD OF USING FLIBANSERIN FOR NEUROPROTECTION | SALIX PHARMACEUTICALS, INC. | 2015-02-26 | — | — | US | disclosed |
| US-20140044803-A1 | METHOD OF USING FLIBANSERIN FOR NEUROPROTECTION | SPROUT PHARMACEUTICALS INC (US) | 2014-02-13 | — | — | US | disclosed |
| US-20120035185-A1 | Method of Using Flibanserin for Neuroprotection | SPROUT PHARMACEUTICALS, INC. | 2012-02-09 | — | — | US | disclosed |
| WO-2010128516-A2 | PROCESS FOR THE PREPARATION OF FLIBANSERIN INVOLVING NOVEL INTERMEDIATES | SYMED LABS LIMITED (IN) | 2010-11-11 | — | — | WO | disclosed |
| US-20060160822-A1 | Method of Using Flibanserin for Neuroprotection | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2006-07-20 | — | — | US | disclosed |
| US-20040235861-A1 | Method of using flibanserin for neuroprotection | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-11-25 | — | — | US | disclosed |
| US-20030060475-A1 | Method of using flibanserin for neuroprotection | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235861-A1 | Method of using flibanserin for neuroprotection | FLNB, BDNF, NLN | ADRA1D 472/4885ADRA1A 504/4885ADRA1B 102/4885 |
| US-20150057290-A1 | METHOD OF USING FLIBANSERIN FOR NEUROPROTECTION | FLNB, BDNF, NLN | ADRA1D 393/4885ADRA1A 418/4885ADRA1B 97/4885 |
| US-20030060475-A1 | Method of using flibanserin for neuroprotection | FLNB, BDNF, NLN | ADRA1D 472/4885ADRA1A 504/4885ADRA1B 102/4885 |
| US-20140044803-A1 | METHOD OF USING FLIBANSERIN FOR NEUROPROTECTION | FLNB, BDNF, NLN | ADRA1D 393/4885ADRA1A 418/4885ADRA1B 97/4885 |
| US-20060160822-A1 | Method of Using Flibanserin for Neuroprotection | FLNB, BDNF, NLN | ADRA1D 393/4885ADRA1A 418/4885ADRA1B 97/4885 |
| US-20120035185-A1 | Method of Using Flibanserin for Neuroprotection | FLNB, BDNF, NLN | ADRA1D 393/4885ADRA1A 418/4885ADRA1B 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.